Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.
The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.
Intelligent Bio Solutions Inc. reported strong growth for its fiscal second quarter ended December 31, 2025, while remaining loss-making. Revenue rose to $896,774, a 48% year-over-year increase, driven by reader sales of $246,519 (up 104%) and cartridge sales of $516,754 (up 33%).
For the first half of fiscal 2026, revenue reached $2.01 million, up 36% year-over-year, with gross profit margins improving to 49% from 39%. Despite this, the company recorded a net loss of $2.68 million for the quarter and $5.66 million for the six months.
The company closed a $10.0 million private placement with healthcare-focused institutional investors, generating $9.40 million in net proceeds received on January 2, 2026, to support working capital, its FDA 510(k) submission, and international expansion. As of December 31, 2025, total assets were $17.65 million and shareholders’ equity was $10.89 million.
Intelligent Bio Solutions Inc. reported higher revenue but continued losses for the quarter ended December 31, 2025. Revenue rose to $896,774 from $607,494 a year earlier, driven by new customers and stronger cartridge reorders, with gross margin improving to 48.69%.
Despite this growth, the company recorded a quarterly net loss attributable to Intelligent Bio Solutions of $2,677,590 and a six‑month net loss of $5,660,596. Cash and cash equivalents were $740,371 at December 31, 2025, plus a shareholder subscription receivable of $9,402,105 that was collected on January 2, 2026.
Shareholders’ equity increased to $10,889,811, supported by at‑the‑market share sales, warrant exercises, and a $10.0 million December 2025 private placement. However, management states that expected operating losses and limited cash resources raise substantial doubt about the company’s ability to continue as a going concern without additional financing.
Intelligent Bio Solutions Inc. filed a current report stating that it has issued a press release announcing preliminary, unaudited revenue results for its fiscal second quarter ended December 31, 2025. The press release is included as Exhibit 99.1.
The company clarifies that this information is being furnished, not filed, so it is not subject to certain liability provisions under U.S. securities laws and will only be incorporated into other filings if specifically referenced.
Intelligent Bio Solutions Inc. announced that it has started a clinical study program to support a new FDA 510(k) submission seeking U.S. market clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The update was shared via a furnished press release attached as an exhibit.
Intelligent Bio Solutions Inc. is registering 6,896,550 shares of common stock for resale by existing investors. These shares consist of 105,000 shares already outstanding and 6,791,550 shares issuable upon exercise of Series L Pre-Funded Warrants and Series K‑1 and K‑2 common stock purchase warrants that were issued in a December 31, 2025 private placement. The company will not receive any proceeds from the resale of these shares, but could receive up to approximately $18.87 million if all 6,791,550 warrant shares are exercised for cash.
The private placement raised about $10.0 million in gross proceeds for working capital and general corporate purposes. As of January 2, 2026, 1,216,142 shares of common stock were outstanding. The filing notes that the resale represents a large block relative to current outstanding shares and could pressure the stock price if sold quickly. The company recently completed a 1‑for‑10 reverse stock split and has regained compliance with Nasdaq’s $1.00 minimum bid price requirement.
Intelligent Bio Solutions Inc. has filed a resale registration statement covering 6,896,550 shares of common stock for selling stockholders. These shares stem from a December 31, 2025 private placement of common stock and warrants, including 105,000 already issued shares and shares underlying Series L pre-funded warrants and Series K-1 and K-2 warrants. The company received approximately $10.0 million in gross proceeds from that private placement at a combined purchase price of $4.35 per share (or pre-funded warrant) plus accompanying warrants.
The company will not receive proceeds from the resale of these shares, but could receive up to about $18.87 million if all 6,791,550 underlying warrant shares are exercised for cash at $0.01 for pre-funded warrants and $4.10 for Series K-1 and K-2 warrants. Shares outstanding were 1,216,142 as of January 2, 2026; this is a baseline figure, not the amount being offered. Intelligent Bio Solutions is an emerging growth medical technology company focused on its Intelligent Fingerprinting drug screening system and has postponed further development of its biosensor platform pending resolution of licensing issues.
Recent corporate actions include a 1-for-10 reverse stock split effective December 15, 2025, implemented to regain compliance with Nasdaq’s $1.00 minimum bid price rule, with Nasdaq subsequently confirming compliance on January 7, 2026. The prospectus notes that the large number of shares registered for resale could pressure the stock price if sold quickly and highlights ongoing risks related to maintaining Nasdaq listing standards.
Intelligent Bio Solutions Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received notice that its common stock had closed below the required $1.00 per share for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk under Listing Rule 5550(a)(2).
On January 7, 2026, Nasdaq’s Listing Qualifications Staff notified the company that it is back in compliance because the closing bid price of its common stock was at or above $1.00 per share for 14 consecutive business days from December 16, 2025 to January 6, 2026. Nasdaq has indicated that the matter is now closed.
Intelligent Bio Solutions Inc. reported that Nasdaq notified the company on December 15, 2025 that its common stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s Bid Price Rule. The notice does not immediately remove the stock from the Nasdaq Capital Market, and the company has until June 15, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
Nasdaq may grant a further 180-day compliance period if other listing standards are satisfied, but this is not assured, and the stock could become subject to delisting, with the company able to appeal to a Nasdaq Hearings Panel. To address the issue, the company filed a Certificate of Amendment to implement a 1-for-10 reverse stock split effective late on December 15, 2025, with shares trading on a split-adjusted basis on December 16, 2025.
Intelligent Bio Solutions Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective at 11:59 p.m. Eastern Time on December 15, 2025.
At the effective time, every 10 issued and outstanding shares will be combined into 1 share, with the par value remaining $0.01. As a result, common shares outstanding will decrease from approximately 9,595,335 as of December 14, 2025 to approximately 959,533 immediately after the split, while authorized common shares will stay at 100 million.
Outstanding stock options, restricted stock units, warrants and the share reserve under the 2019 Plan will be adjusted proportionately. Split-adjusted shares are expected to begin trading on The Nasdaq Capital Market on December 16, 2025 under the symbol INBS with a new CUSIP number. No fractional shares will be issued; instead, holders will receive cash based on the average closing prices over the five trading days before the split. The company also provided post-split versions of recent share and loss-per-share data.